Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of NeoGenomics, Inc. (NASDAQ:NEO). In a filing disclosed on September 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in NeoGenomics stock on August 7th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 8/28/2026.
• Purchased $15,001 – $50,000 in shares of Quanta Services (NYSE:PWR) on 8/27/2026.
• Purchased $15,001 – $50,000 in shares of Eaton (NYSE:ETN) on 8/27/2026.
• Sold $15,001 – $50,000 in shares of NIKE (NYSE:NKE) on 8/27/2026.
• Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Wheaton Precious Metals (NYSE:WPM) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 8/26/2026.
• Sold $15,001 – $50,000 in shares of Lamar Advertising (NASDAQ:LAMR) on 8/25/2026.
• Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/25/2026.

NeoGenomics Stock Performance

Shares of NeoGenomics stock opened at $17.32 on Friday. The business’s fifty day simple moving average is $15.91 and its 200 day simple moving average is $11.75. The company has a current ratio of 3.60, a quick ratio of 3.35 and a debt-to-equity ratio of 0.48. NeoGenomics, Inc. has a 12 month low of $7.07 and a 12 month high of $19.76. The firm has a market capitalization of $2.23 billion, a P/E ratio of -43.30 and a beta of 1.75.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.02. NeoGenomics had a negative return on equity of 1.99% and a negative net margin of 6.77%.The firm had revenue of $201.66 million during the quarter, compared to the consensus estimate of $196.93 million. During the same quarter in the prior year, the company earned $0.03 EPS. The business’s revenue for the quarter was up 11.2% on a year-over-year basis. As a group, analysts anticipate that NeoGenomics, Inc. will post -0.09 EPS for the current year.

Institutional Investors Weigh In On NeoGenomics

Institutional investors have recently added to or reduced their stakes in the business. First Light Asset Management LLC increased its stake in shares of NeoGenomics by 26.2% in the second quarter. First Light Asset Management LLC now owns 12,279,523 shares of the medical research company’s stock worth $179,158,000 after purchasing an additional 2,549,545 shares in the last quarter. First Trust Advisors LP purchased a new stake in shares of NeoGenomics during the 1st quarter valued at approximately $45,725,000. Geode Capital Management LLC boosted its holdings in NeoGenomics by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 3,176,644 shares of the medical research company’s stock worth $37,364,000 after buying an additional 44,733 shares during the period. Dimensional Fund Advisors LP boosted its holdings in NeoGenomics by 9.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,674,335 shares of the medical research company’s stock worth $19,842,000 after buying an additional 225,588 shares during the period. Finally, American Capital Management Inc. grew its stake in NeoGenomics by 120.9% in the 3rd quarter. American Capital Management Inc. now owns 2,345,263 shares of the medical research company’s stock valued at $18,105,000 after buying an additional 1,283,390 shares in the last quarter. 98.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on NEO shares. Weiss Ratings raised shares of NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 14th. Benchmark lifted their price objective on shares of NeoGenomics from $11.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. TD Cowen reiterated a “buy” rating on shares of NeoGenomics in a research note on Wednesday, July 15th. Wall Street Zen raised shares of NeoGenomics from a “hold” rating to a “buy” rating in a research report on Saturday, June 27th. Finally, Needham & Company LLC raised their price target on shares of NeoGenomics from $15.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $17.67.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About NeoGenomics

NeoGenomics, Inc is a provider of cancer-focused diagnostic testing and contract research services. The company operates clinical laboratories that support physicians, hospitals and other healthcare organizations with information used to help diagnose, classify and monitor cancer.

Its testing services include anatomic pathology, immunohistochemistry, flow cytometry, cytogenetics, fluorescence in situ hybridization, molecular testing and next-generation sequencing. NeoGenomics also provides biopharmaceutical companies with clinical trial testing, central laboratory services, biomarker development and other research services intended to support the development of oncology therapies and companion diagnostics.

Founded in 1999, NeoGenomics serves healthcare providers and pharmaceutical and biotechnology customers primarily in the United States, with additional capabilities supporting international clinical research programs.